RESTON, Va., Feb. 25, 2021 /PRNewswire/ -- Leidos (NYSE:
LDOS), a FORTUNE® 500 science and technology leader, was recently
awarded a new project agreement by the Defense Threat Reduction
Agency (DTRA) to conduct clinical studies of therapeutics for
treating COVID-19. The cost-plus-fixed-fee agreement was awarded
through the Medical CBRN Defense Consortium. It holds a base value
of $22 million and a base period of
performance of 24 months.
"This award reinforces our commitment to fighting this deadly
pandemic," said Liz Porter, Leidos
Health Group president. "We are proud to conduct these clinical
trials and support our customers' mission to develop life-saving
drugs, vaccines and therapeutics for the men and women of our armed
forces."
Through this contract, Leidos will use a new clinical trial
prototype to enable real-time data collection, which will support
rapid initiation, amendment and evaluation of studies. Leidos will
use the prototype to simultaneously conduct two clinical studies
using new drug combinations to treat COVID-19. The studies will
seek safe and effective doses and regimens for coronavirus
patients. The trials will also pursue enhancements to military
success by improving long-term lung function and reducing
neurocognitive deficits caused by COVID-19.
The Leidos trial prototype aims to enable quicker evaluations
and improvements as the study evolves. It uses an electronic data
capture system to collect, evaluate and assess symptom severity as
well as clinical outcomes in real-time for patients. This could
enable the trial's data and safety monitoring board to quickly
evaluate potential safety signals or evidence of efficacy. The
prototype is also designed to analyze the need for additional
patients to show statistical significance. These evaluations could
improve potential Phase 3 studies and demonstrate efficacy using
the selected drug combination.
Leidos is collaborating with Personal Health Insights, Inc.,
Syneos Health and SCOPE International USA, Inc., on this prototype project.
About Leidos
Leidos is a Fortune 500® information technology, engineering,
and science solutions and services leader working to solve the
world's toughest challenges in the defense, intelligence, homeland
security, civil, and health markets. The company's 39,000 employees
support vital missions for government and commercial customers.
Headquartered in Reston, Va.,
Leidos reported annual revenues of approximately $12.30 billion for the fiscal year ended
January 1, 2021. For more
information, visit www.Leidos.com.
Statements in this announcement, other than historical data and
information, constitute forward-looking statements that involve
risks and uncertainties. A number of factors could cause our actual
results, performance, achievements, or industry results to be very
different from the results, performance, or achievements expressed
or implied by such forward-looking statements. Some of these
factors include, but are not limited to, the risk factors set forth
in the company's Annual Report on Form 10-K for the period ended
January 1, 2021, and other such
filings that Leidos makes with the SEC from time to time. Due to
such uncertainties and risks, readers are cautioned not to place
undue reliance on such forward-looking statements, which speak only
as of the date hereof.
Contact:
|
Melissa
Dueñas
|
|
(571)
526-6850
|
|
Duenasml@leidos.com
|
|
|
|
Thomas
Doheny
|
|
(571)
474-4735
|
|
Dohenyt@leidos.com
|
View original content to download
multimedia:http://www.prnewswire.com/news-releases/dtra-awards-leidos-project-to-conduct-clinical-trials-for-covid-19-therapeutics-301235381.html
SOURCE Leidos